Experimental gene therapy aims to save sight in rare eye disease
Disease control
Recruiting now
This study tests a gene therapy called laruparetigene zovaparvovec (AGTC-501) given in both eyes to 10 males aged 12–50 with X-linked retinitis pigmentosa, a genetic condition that causes vision loss. The main goal is to check safety and see if the treatment can preserve or impro…
Phase: PHASE2 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated May 26, 2026 15:29 UTC